Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2026)

Ginkgo Bioworks Holdings has reported Research & Development for 7 years, with the latest figure at $49.9 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 29.61% year-over-year to $49.9 million; the trailing twelve-month figure through Mar 2026 stood at $222.8 million (down 37.87% YoY), and the FY2025 full-year result was $243.8 million, down 42.51% from the prior year.
• Research & Development for Q1 2026 stood at $49.9 million, roughly flat from $50.1 million in the prior quarter.
• The five-year high for Research & Development was $323.6 million in Q1 2022, with the low at $49.9 million in Q1 2026.
• Historically, Research & Development has averaged $138.3 million across 5 years, with a median of $134.2 million in 2024.
• The largest YoY upside for Research & Development was 457.47% in 2022 against a maximum downside of 81.98% in 2022.
• Ginkgo Bioworks Holdings' Research & Development stood at $177.5 million in 2022, then plunged by 34.08% to $117.0 million in 2023, then slumped by 34.74% to $76.4 million in 2024, then tumbled by 34.37% to $50.1 million in 2025, then dropped by 0.41% to $49.9 million in 2026.
• The last three Research & Development figures came in at $49.9 million (Q1 2026), $50.1 million (Q4 2025), and $69.4 million (Q3 2025), per Business Quant data.